About Market Research Report Store Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests. Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.
MedImmune, LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile ID: 269404 December 2016 Region: United States 140 pagesGlobalData Single User License - $250.00 Corporate Users License - $500.00
Enterprise Wide License - $750.00
MRRS adds "MedImmune, LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile" latest studies, published in December 2016. It is a professional and in-depth study.
Summary MedImmune, LLC (MedImmune), is a biotechnology company operating as the global biologics subsidiary of AstraZeneca. It focuses on the research, development, manufacture and marketing of biologics to address some of the major medical needs. The company develops therapeutic proteins, monoclonal antibodies and other next-generation molecules targeting diseasing the areas of oncology; respiratory, inflammation and autoimmune; and cardiovascular and metabolic diseases. The company’s product portfolio includes products for respiratory syncytial virus; influenza vaccine; and organic thiophosphate cytoprotective agent. The company operates three R&D centers in Gaithersburg, Maryland; Cambridge, the UK; and Mountain View, California. MedImmune is headquartered in Gaithersburg, Maryland, the US. MedImmune, LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope – Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. – Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. – Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. – Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. – Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector. – Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
– Business Description – A brief description of the company’s operations. – Key Employees – A list of the key executives of the company. – Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company. – Key Competitors – A list of the key competitors of the company. – Key Recent Developments – A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements – The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period. Understand the company’s business segments’ expansion / divestiture strategy – The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy. Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company – Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios. Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. – The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors. Stay up-to-date on the major developments affecting the company – Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research – Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.
Table Of Contents Table of Contents 2 List of Tables 5
List of Figures 7 MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 8 MedImmune, LLC, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 9 MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 10 MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 11 MedImmune, LLC, Medical Devices Deals, 2010 to YTD 2016 13 MedImmune, LLC, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 14 MedImmune, LLC, Pharmaceuticals & Healthcare, Deal Details 22 Venture Financing 22 G1 Therapeutics Raises USD47 Million in Series C Financing 22 G1 Therapeutics Raises USD33 Million in Series B Financing 24 Definiens Raises USD20.3 Million in Venture Financing Round 26 Catabasis Pharma Raises US$32.4 Million In Series B Financing 28 G1 Therapeutics Raises US$12.5 Million In Series A Financing 30 Inotek Pharma Raises US$21 Million In Venture Financing 31 AesRx Raises US$1.35 Million In Venture Financing 33 Applied Genetic Technologies Raises US$37.5 Million In Series B Financing 34 Ambit Biosciences Raises US$25 Million In First Tranche Of Venture Financing 36 Definiens Raises US$13 Million In Venture Financing 38 Coferon Raises US$12 Million In Series B Venture Financing Round 40 ADC Therapeutics To Raise US$50 Million In Venture Financing 41 Catabasis Pharma Secures US$8 Million In Extended Series A Financing 43 NeuProtect Secures Second Venture Financing Round 45 Inotek Pharma Raises An Additional US$9.35 Million In Venture Financing 46 Ambit Biosciences Secures US$30 Million In Series D-2 Financing 48 Catabasis Pharma Secures US$14.5 Million In The Second Tranche Of Series A Financing Round 51 Corridor Pharma Secures US$15 Million In Series A Financing 53 VentiRx Pharma Raises US$25 Million In Additional Series A Financing 55 Partnerships 57 MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 57 AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 59
Cepheid, MedImmune and Combacte Enter into Agreement 61 Rani Therapeutics Enters into Agreement with MedImmune 62 Igenica Biotherapeutics Enters into Research Agreement with MedImmune 63 MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 64 MedImmune Enters into Research Agreement with University of Sheffield 65 Vall d'Hebron Institute of Oncology Enters into Agreement with AstraZeneca 66 MedImmune Enters into Agreement with Juno Therapeutics 67 MedImmune Enters into Research Agreement with Joslin Diabetes Center 68 MedImmune Enters into Research Agreement with COEBP 69 MedImmune Enters into Research Agreement with University of Manchester 70 MedImmune Enters into Co-Development Agreement with National Cancer Institute 71 Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 72 AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 73 Cancer Research UK Forms Joint Venture with MedImmune 75 Advaxis Enters into Agreement with MedImmune 76 MedImmune Enters Into Research Agreement With Cambridge University 77 MedImmune Enters Into Research Agreement With Johns Hopkins University 78 MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 80 MedImmune Enters Into Co-Development Agreement With NGM Biopharma 82 Daiichi Sankyo Enters Into Agreement With Amplimmune To Develop Therapy For Autoimmune Disease 84 PeptiDream Enters into Drug Discovery Agreement with MedImmune 86 Medimmune Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute for Cancer Research 87 Medimmune And Wuxi Apptec Form Joint Venture To Develop Biologic MEDI5117 For Chinese Market 89 PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 90 University Of Michigan Medical School Enters Into Research Agreement With MedImmune 91 AgonOx Enters Into Co-Development Agreement With MedImmune 92 Pfenex Enters Into Collaboration With MedImmune 93 Leica Microsystems Enters Into Co-Marketing Agreement With Definiens 94 MedImmune Enters Into Co-Development Agreement With Inserm Transfert 96
Advanced Cell Diagnostics Enters Into Co-Development Agreement With Definiens 97 Phylogica Enters Into Discovery Collaboration With MedImmune 98 Amplimmune Enters Into Co-Development Agreement With GlaxoSmithKline 99 Licensing Agreements 100 Regeneron Pharma Enters into Licensing Agreement with MedImmune 100 MedImmune Enters into Licensing Agreement with Wacker Biotech 101 MedImmune Enters into Licensing Agreement with 3M Drug Delivery Systems 102 Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 103 Daiichi Sankyo Enters into Licensing Agreement with MedImmune for FluMist 104 MedImmune Enters into Licensing Agreement with Inovio Pharma 105 Shionogi Enters into Licensing Agreement with MedImmune 106 biOasis Enters Into Licensing Agreement With Medimmune For Transcend Brain Delivery Platform 107 MedImmune And Immunocore Enter Into Licensing Agreement To Develop Cancer Therapies 108 Humabs Biomed Enters into Licensing Agreement with MedImmune 110 Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 111 Kolltan Pharma Enters Into Licensing Agreement With MedImmune 113 Axerion Therapeutics Enters Into Licensing Agreement With MedImmune For Alzheimer’s Disease 114 MedImmune To Enter Into Licensing Agreement With Pfizer 115 Ligand Pharma Terminates Licensing Agreement With MedImmune 117 Spirogen Enters Into Licensing Agreement With Genentech 118 Immune Design Enters Into Licensing Agreement With MedImmune 120 Xenome Enters Into Licensing Agreement With MedImmune 121 Asset Transactions 122 Cornerstone Therapeutics Reacquires HMGB1 Protein Technology Platform From MedImmune 122 Acquisition 124 MedImmune Acquires Definiens for USD150 Million 124 MedImmune Acquires Spirogen From Auven Therapeutics For US$440 Million 126 MedImmune Completes Acquisition Of Amplimmune For Up To US$500 Million 128 MedImmune Acquires AlphaCore Pharma, Cholesterol Drug Developer 130 Takeda America Completes Acquisition Of LigoCyte Pharma For US$60 Million 131
Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 134 MedImmune, LLC - Key Competitors 135 Key Employees 136 Locations And Subsidiaries 138 Head Office 138 Other Locations & Subsidiaries 138 Appendix 140 Methodology 140 About GlobalData 140 Contact Us 140 Disclaimer 140
List of Tables MedImmune, LLC, Pharmaceuticals & Healthcare, Key Facts 1 MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 8 MedImmune, LLC, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 9 MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 10 MedImmune, LLC, Deals By Therapy Area, 2010 to YTD 2016 11 MedImmune, LLC, Medical Devices Deals, 2010 to YTD 2016 13 MedImmune, LLC, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 14 G1 Therapeutics Raises USD47 Million in Series C Financing 22 G1 Therapeutics Raises USD33 Million in Series B Financing 24 Definiens Raises USD20.3 Million in Venture Financing Round 26 Catabasis Pharma Raises US$32.4 Million In Series B Financing 28 G1 Therapeutics Raises US$12.5 Million In Series A Financing 30 Inotek Pharma Raises US$21 Million In Venture Financing 31 AesRx Raises US$1.35 Million In Venture Financing 33 Applied Genetic Technologies Raises US$37.5 Million In Series B Financing 34 Ambit Biosciences Raises US$25 Million In First Tranche Of Venture Financing 36 Definiens Raises US$13 Million In Venture Financing 38 Coferon Raises US$12 Million In Series B Venture Financing Round 40 ADC Therapeutics To Raise US$50 Million In Venture Financing 41
Catabasis Pharma Secures US$8 Million In Extended Series A Financing 43 NeuProtect Secures Second Venture Financing Round 45 Inotek Pharma Raises An Additional US$9.35 Million In Venture Financing 46 Ambit Biosciences Secures US$30 Million In Series D-2 Financing 48 Catabasis Pharma Secures US$14.5 Million In The Second Tranche Of Series A Financing Round 51 Corridor Pharma Secures US$15 Million In Series A Financing 53 VentiRx Pharma Raises US$25 Million In Additional Series A Financing 55 MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 57 AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 59 Cepheid, MedImmune and Combacte Enter into Agreement 61 Rani Therapeutics Enters into Agreement with MedImmune 62 Igenica Biotherapeutics Enters into Research Agreement with MedImmune 63 MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 64 MedImmune Enters into Research Agreement with University of Sheffield 65 Vall d'Hebron Institute of Oncology Enters into Agreement with AstraZeneca 66 MedImmune Enters into Agreement with Juno Therapeutics 67 MedImmune Enters into Research Agreement with Joslin Diabetes Center 68 MedImmune Enters into Research Agreement with COEBP 69 MedImmune Enters into Research Agreement with University of Manchester 70 MedImmune Enters into Co-Development Agreement with National Cancer Institute 71 Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 72 AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 73 Cancer Research UK Forms Joint Venture with MedImmune 75 Advaxis Enters into Agreement with MedImmune 76 MedImmune Enters Into Research Agreement With Cambridge University 77 MedImmune Enters Into Research Agreement With Johns Hopkins University 78 MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 80 MedImmune Enters Into Co-Development Agreement With NGM Biopharma 82 Daiichi Sankyo Enters Into Agreement With Amplimmune To Develop Therapy For Autoimmune Disease 84 PeptiDream Enters into Drug Discovery Agreement with MedImmune 86
Medimmune Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute for Cancer Research 87 Medimmune And Wuxi Apptec Form Joint Venture To Develop Biologic MEDI5117 For Chinese Market 89 PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 90 University Of Michigan Medical School Enters Into Research Agreement With MedImmune 91 AgonOx Enters Into Co-Development Agreement With MedImmune 92 Pfenex Enters Into Collaboration With MedImmune 93 Leica Microsystems Enters Into Co-Marketing Agreement With Definiens 94 MedImmune Enters Into Co-Development Agreement With Inserm Transfert 96 Advanced Cell Diagnostics Enters Into Co-Development Agreement With Definiens 97 Phylogica Enters Into Discovery Collaboration With MedImmune 98 Amplimmune Enters Into Co-Development Agreement With GlaxoSmithKline 99 Regeneron Pharma Enters into Licensing Agreement with MedImmune 100 MedImmune Enters into Licensing Agreement with Wacker Biotech 101 MedImmune Enters into Licensing Agreement with 3M Drug Delivery Systems 102 Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 103 Daiichi Sankyo Enters into Licensing Agreement with MedImmune for FluMist 104 MedImmune Enters into Licensing Agreement with Inovio Pharma 105 Shionogi Enters into Licensing Agreement with MedImmune 106 biOasis Enters Into Licensing Agreement With Medimmune For Transcend Brain Delivery Platform 107 MedImmune And Immunocore Enter Into Licensing Agreement To Develop Cancer Therapies 108 Humabs Biomed Enters into Licensing Agreement with MedImmune 110 Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 111 Kolltan Pharma Enters Into Licensing Agreement With MedImmune 113 Axerion Therapeutics Enters Into Licensing Agreement With MedImmune For Alzheimer’s Disease 114 MedImmune To Enter Into Licensing Agreement With Pfizer 115 Ligand Pharma Terminates Licensing Agreement With MedImmune 117 Spirogen Enters Into Licensing Agreement With Genentech 118 Immune Design Enters Into Licensing Agreement With MedImmune 120 Xenome Enters Into Licensing Agreement With MedImmune 121
Cornerstone Therapeutics Reacquires HMGB1 Protein Technology Platform From MedImmune 122 MedImmune Acquires Definiens for USD150 Million 124 MedImmune Acquires Spirogen From Auven Therapeutics For US$440 Million 126 MedImmune Completes Acquisition Of Amplimmune For Up To US$500 Million 128 MedImmune Acquires AlphaCore Pharma, Cholesterol Drug Developer 130 Takeda America Completes Acquisition Of LigoCyte Pharma For US$60 Million 131 Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 134 MedImmune, LLC, Key Competitors 135 MedImmune, LLC, Key Employees 136 MedImmune, LLC, Other Locations 138 MedImmune, LLC, Subsidiaries 139
List of Figures MedImmune, LLC, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1 MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1 MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1 MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1 MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 8 MedImmune, LLC, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 9 MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 10 MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 11 MedImmune, LLC, Medical Devices Deals, 2010 to YTD 2016 13
Ask a sample and any further questions, please feel free to contact us: Tel: +00-1-626-3463946 - U.S Email: shirley@marketresearchreportstore.com Web: http://www.marketresearchreportstore.com/